Bio Path Holdings Stock Odds of Future Stock Price Finishing Over 1.04
| BPTH Stock | USD 1.04 0.07 6.31% |
Bio |
Bio Path Target Price Odds to finish over 1.04
The tendency of Bio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.04 | 90 days | 1.04 | about 23.51 |
Based on a normal probability distribution, the odds of Bio Path to move above the current price in 90 days from now is about 23.51 (This Bio Path Holdings probability density function shows the probability of Bio Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Bio Path Holdings has a beta of -0.7 suggesting as returns on the benchmark increase, returns on holding Bio Path are expected to decrease at a much lower rate. During a bear market, however, Bio Path Holdings is likely to outperform the market. Moreover Bio Path Holdings has an alpha of 1.1616, implying that it can generate a 1.16 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Bio Path Price Density |
| Price |
Predictive Modules for Bio Path
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bio Path Holdings. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bio Path's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Bio Path Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Bio Path is not an exception. The market had few large corrections towards the Bio Path's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bio Path Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bio Path within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.16 | |
β | Beta against Dow Jones | -0.7 | |
σ | Overall volatility | 0.18 | |
Ir | Information ratio | 0.07 |
Bio Path Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bio Path for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bio Path Holdings can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Bio Path Holdings is way too risky over 90 days horizon | |
| Bio Path Holdings has some characteristics of a very speculative penny stock | |
| Bio Path Holdings appears to be risky and price may revert if volatility continues | |
| Bio Path Holdings has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (16.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from finance.yahoo.com: Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity |
Bio Path Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Bio Stock often depends not only on the future outlook of the current and potential Bio Path's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Bio Path's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 478 K | |
| Cash And Short Term Investments | 1.1 M |
Bio Path Technical Analysis
Bio Path's future price can be derived by breaking down and analyzing its technical indicators over time. Bio Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Bio Path Holdings. In general, you should focus on analyzing Bio Stock price patterns and their correlations with different microeconomic environments and drivers.
Bio Path Predictive Forecast Models
Bio Path's time-series forecasting models is one of many Bio Path's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Bio Path's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Bio Path Holdings
Checking the ongoing alerts about Bio Path for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Bio Path Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Bio Path Holdings is way too risky over 90 days horizon | |
| Bio Path Holdings has some characteristics of a very speculative penny stock | |
| Bio Path Holdings appears to be risky and price may revert if volatility continues | |
| Bio Path Holdings has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (16.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from finance.yahoo.com: Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity |
Check out Bio Path Backtesting, Bio Path Valuation, Bio Path Correlation, Bio Path Hype Analysis, Bio Path Volatility, Bio Path History as well as Bio Path Performance. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.